{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:01:16Z","timestamp":1775898076894,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.leukres.2021.106521","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T21:17:14Z","timestamp":1612473434000},"page":"106521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-9245","authenticated-orcid":false,"given":"Semih","family":"Ba\u015fc\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu\u011f\u00e7e Nur","family":"Yi\u011feno\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Bak\u0131rta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"Uncu Ulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samet","family":"Yaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merih","family":"K\u0131z\u0131l \u00c7akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.leukres.2021.106521_bib0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2016-01-643569","article-title":"The updated who classification of hematological malignancies: the 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"blood J."},{"issue":"January (1)","key":"10.1016\/j.leukres.2021.106521_bib0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"November (19)","key":"10.1016\/j.leukres.2021.106521_bib0015","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106521_bib0020","unstructured":"Health Statistics Yearbook 2014, General directorate of health research."},{"issue":"7","key":"10.1016\/j.leukres.2021.106521_bib0025","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1158\/1078-0432.CCR-12-2837","article-title":"Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties","volume":"19","author":"Sarkozy","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2021.106521_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"issue":"May (5)","key":"10.1016\/j.leukres.2021.106521_bib0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"issue":"November (11)","key":"10.1016\/j.leukres.2021.106521_bib0040","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"May (5)","key":"10.1016\/j.leukres.2021.106521_bib0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"issue":"September (14)","key":"10.1016\/j.leukres.2021.106521_bib0050","first-page":"987","article-title":"A predictive model for aggressive Non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"January (4)","key":"10.1016\/j.leukres.2021.106521_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"July (19)","key":"10.1016\/j.leukres.2021.106521_bib0060","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"June (11)","key":"10.1016\/j.leukres.2021.106521_bib0065","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","article-title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"109","author":"Nyman","year":"2007","journal-title":"Blood"},{"issue":"October (28)","key":"10.1016\/j.leukres.2021.106521_bib0070","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106521_bib0075","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-104-6-757","article-title":"Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD","volume":"104","author":"Shipp","year":"1986","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.leukres.2021.106521_bib0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9343(77)90230-3","article-title":"Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy","volume":"63","author":"Fisher","year":"1977","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2021.106521_bib0085","article-title":"Predictive model for prognosis in advanced diffuse histiocytic lymphoma","volume":"46","author":"Danieu","year":"1986","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2021.106521_bib0090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1991.9.2.220","article-title":"Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B","volume":"9","author":"Hoskins","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"January (1)","key":"10.1016\/j.leukres.2021.106521_bib0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj030","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience","volume":"17","author":"Savage","year":"2006","journal-title":"Ann. Oncol."},{"issue":"February (1)","key":"10.1016\/j.leukres.2021.106521_bib0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1751-553X.2007.00900.x","article-title":"Adjuvant radiotherapy to an initial bulky mass in diffuse large B-cell lymphoma: lack of survival benefit","volume":"30","author":"Tomita","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"issue":"September","key":"10.1016\/j.leukres.2021.106521_bib0105","first-page":"vii78","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106521_bib0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.6004\/jnccn.2016.0023","article-title":"Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology","volume":"14","author":"Zelenetz","year":"2016","journal-title":"JNCCN Jo. Natl. Compr. Cancer Network"},{"issue":"2","key":"10.1016\/j.leukres.2021.106521_bib0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"issue":"January (1)","key":"10.1016\/j.leukres.2021.106521_bib0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2021.106521_bib0125","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.leukres.2021.106521_bib0130","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"November (6)","key":"10.1016\/j.leukres.2021.106521_bib0135","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"November (19)","key":"10.1016\/j.leukres.2021.106521_bib0140","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"September (27)","key":"10.1016\/j.leukres.2021.106521_bib0145","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106521_bib0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cger.2015.08.005","article-title":"Long-term toxicity of cancer treatment in older patients","volume":"32","author":"Shahrokni","year":"2016","journal-title":"Clin. Geriatr. Med."},{"issue":"September (25)","key":"10.1016\/j.leukres.2021.106521_bib0155","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued Risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: Final and long-term analysis of southwest oncology group study S8736","volume":"34","author":"Stephens","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106521_bib0160","first-page":"103","article-title":"Long-term toxicity of chemotherapy and radiotherapy in lymphoma survivors: Optimizing treatment for individual patients","volume":"13","author":"Hodgson","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"October (4)","key":"10.1016\/j.leukres.2021.106521_bib0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.adro.2019.07.010","article-title":"Does the Incidence of treatment-related toxicity plateau after radiation therapy: the long-term impact of integral dose in Hodgkin\u2019s Lymphoma survivors","volume":"4","author":"Holtzman","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106521_bib0170","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/cam4.2798","article-title":"Significance of bulky mass and residual tumor\u2014treated with or without consolidative radiotherapy\u2014to the risk of relapse in DLBCL patients","volume":"9","author":"Tokola","year":"2020","journal-title":"Cancer Med."},{"issue":"September (12)","key":"10.1016\/j.leukres.2021.106521_bib0175","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"July (1)","key":"10.1016\/j.leukres.2021.106521_bib0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2007-01-041871","article-title":"How I treat patients with diffuse large B-cell lymphoma","volume":"110","author":"Armitage","year":"2007","journal-title":"Blood"},{"issue":"November (31)","key":"10.1016\/j.leukres.2021.106521_bib0185","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2021.106521_bib0190","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"issue":"October (10)","key":"10.1016\/j.leukres.2021.106521_bib0195","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00277-010-0964-7","article-title":"Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy","volume":"89","author":"Song","year":"2010","journal-title":"Ann. Hematol."},{"issue":"August (2)","key":"10.1016\/j.leukres.2021.106521_bib0200","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V74.2.558.558","article-title":"Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen","volume":"74","author":"Coiffier","year":"1989","journal-title":"Blood"},{"issue":"December (3)","key":"10.1016\/j.leukres.2021.106521_bib0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12288-014-0479-9","article-title":"Post-treatment PET\u2013CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass","volume":"31","author":"Takasaki","year":"2015","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"2","key":"10.1016\/j.leukres.2021.106521_bib0210","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/bjc.1989.57","article-title":"Prognostic factors in high and intermediate grade non-Hodgkin\u2019s lymphoma","volume":"59","author":"Cowan","year":"1989","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2021.106521_bib0215","unstructured":"R. Eren et al., \u201cVolume: 28 Year: 2018 ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI,\u201d Int. J. Hematol. Oncol. Artic., no. 4."},{"issue":"May (2)","key":"10.1016\/j.leukres.2021.106521_bib0220","first-page":"81","article-title":"Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results","volume":"36","author":"Ad\u0131yaman","year":"2019","journal-title":"Turkish J. Haematol. Off. J. Turkish Soc. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:39Z","timestamp":1758934839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":44,"alternative-id":["S0145212621000229"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106521","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106521"}}